UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/004,504	10/26/2001	Yi-Ren Woo	1416.03US01	4675
27367 7590 08/24/2007 WESTMAN CHAMPLIN & KELLY, P.A.			EXAMINER	
SUITE 1400			SWEET, THOMAS	
900 SECOND AVENUE SOUTH MINNEAPOLIS, MN 55402-3319			ART UNIT	PAPER NUMBER
			3738	
			MAIL DATE	DELIVERY MODE
			08/24/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

_• <u> </u>	<i>i</i> ,	Application No.	Applicant(s)			
		Application No.				
Office Action Summary		10/004,504	WOO ET AL.			
		Examiner	Art Unit			
		Thomas J. Sweet	3738			
Period fo	The MAILING DATE of this communication apports Reply	ears on the cover sheet with the c	orrespondence address			
WHIC - Exte after - If NC - Failu Any	ORTENED STATUTORY PERIOD FOR REPLY CHEVER IS LONGER, FROM THE MAILING DANSIONS of time may be available under the provisions of 37 CFR 1.13 SIX (6) MONTHS from the mailing date of this communication. Operiod for reply is specified above, the maximum statutory period we are to reply within the set or extended period for reply will, by statute, reply received by the Office later than three months after the mailing ed patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tim vill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).			
Status						
1)⊠	Responsive to communication(s) filed on <u>19 June 2007</u> .					
2a)⊠	This action is FINAL . 2b) ☐ This action is non-final.					
3) 🗌						
	closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.					
Disposit	ion of Claims					
5)□ 6)⊠ 7)□	Claim(s) 1-19,22 and 40-56 is/are pending in the 4a) Of the above claim(s) is/are withdraw Claim(s) is/are allowed. Claim(s) 1-19, 22 and 40-56 is/are rejected. Claim(s) is/are objected to. Claim(s) are subject to restriction and/or	vn from consideration.				
Applicat	ion Papers					
10)	The specification is objected to by the Examine The drawing(s) filed on is/are: a) acce Applicant may not request that any objection to the of Replacement drawing sheet(s) including the correct The oath or declaration is objected to by the Ex	epted or b) objected to by the I drawing(s) be held in abeyance. See ion is required if the drawing(s) is ob	e 37 CFR 1.85(a). jected to. See 37 CFR 1.121(d).			
Priority (under 35 U.S.C. § 119					
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 						
2) Notice 3) Infor	ce of References Cited (PTO-892) ce of Draftsperson's Patent Drawing Review (PTO-948) mation Disclosure Statement(s) (PTO/SB/08) er No(s)/Mail Date	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal F 6) Other:	ate			

Application/Control Number: 10/004,504

Art Unit: 3738

DETAILED ACTION

Response to Arguments

Applicant's arguments, see page 8, filed 6/19/07, with respect to the claim objections have been fully considered and are persuasive. The objection of claims 1-19, 22, 23 and 40-56 has been withdrawn.

Applicant's arguments filed 06/19/2007 have been fully considered but they are not persuasive. In response to applicant's arguments against the references individually, one cannot show nonobviousness by attacking references individually where the rejections are based on combinations of references. See *In re Keller*, 642 F.2d 413, 208 USPQ 871 (CCPA 1981); *In re Merck & Co.*, 800 F.2d 1091, 231 USPQ 375 (Fed. Cir. 1986). Additionally, the MacGregor reference is not destroyed by the combination, since the hydrogel of Carlyle et al is bioabsorbable and any portion of the MacGregor later exposed to the blood stream would function as intended. Coating over pores places filler in the pores so the claim amendments of having filler located in the pores does not define over the prior rejection.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 1-19, 22 and 40-56 are rejected under 35 U.S.C. 103(a) as being unpatentable over MacGregor in view of Carlyle et al. MacGregor discloses a heart valve (col 3-6) including a rigid carbonaceous solid occluder with a porous surface. However, MacGregor does not disclose

Application/Control Number: 10/004,504

Art Unit: 3738

a filler consisting of mixtures of hydrogel, structural protein and bioactive agents. Carlyle et al discloses a coating for heart valves occluders consisting of mixtures of hydrogel, structural protein and bioactive agents for the purpose of causing cell adhesion to the surface. It would have been obvious to one of ordinary skill in the art at the time the invention was made to coat the occluder of MacGregor with the coating material of Carlyle et al (thereby filling the pores of the occluder) in order to promote cell adhesion to the surface.

With regard to claims 3, 4, 42, 43 and 52, the surface in figures of Carlyle et al appears smooth and page 3 states that it is suitable for contact with the patients bodily fluids.

With regard to claim 5, see page 12, 2nd paragraph of Carlyle et al.

With regard to claims 6 and 7, see page 7, 2nd paragraph of Carlyle et al.

With regard to claims 8, 44 and 53, see page 22, 2nd paragraph of Carlyle et al.

With regard to claims 9-14, 45-47 and 54-55, see page 7, 2nd paragraph of Carlyle et al.

With regard to claims 15 and 48, both of Carlyle et al and MacGregor mention the use of anticoagulants. However, the filler as disclosed does not include anticoagulant. It is well known in the art of hydrogels to include anticoagulants therein to prevent clotting. It would have been obvious to one of ordinary skill in the art at the time the invention was made to include anticoagulant in the hydrogel of Carlyle in order to prevent clotting.

With regard to claim 16-17 and 51, MacGregor discloses network of interconnected interstitial pores below the surface.

With regard to claim 18, collagen is a nutrient of Carlyle et al.

With regard to claim 19, see page 25, 2nd paragraph of Carlyle et al.

Art Unit: 3738

With regard to claim 56, this is a non-elected member of a Markush grouping. Claims 1, 40 and 49 were rejected on carbonaceous solid.

Conclusion

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Thomas J. Sweet whose telephone number is 571-272-4761. The examiner can normally be reached on 5:45am - 4:15pm, Tu-Th.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Corrine M. McDermott can be reached on 571-272-4754. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/004,504

Art Unit: 3738

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Page 5

Thomas J Sweet

Examiner AU 3738